Overview

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Bococizumab